Herzyk DJ[au] - Search Results

Year	Number of Results
1988	2
1989	4
1990	1
1991	1
1992	3
1993	2
1995	2
1996	2
1997	1
1999	1
2000	2
2001	2
2002	2
2003	3
2004	2
2005	1
2007	1
2009	1
2010	1
2016	1
2018	1
2020	1
2022	0

1

Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies.

Herzyk DJ, Haggerty HG. Herzyk DJ, et al. AAPS J. 2018 Feb 7;20(2):28. doi: 10.1208/s12248-017-0184-3. AAPS J. 2018. PMID: 29417397 Review.

2

Flow cytometry in the preclinical development of biopharmaceuticals.

Gossett KA, Narayanan PK, Williams DM, Gore ER, Herzyk DJ, Hart TK, Sellers TS. Gossett KA, et al. Among authors: herzyk dj. Toxicol Pathol. 1999 Jan-Feb;27(1):32-7. doi: 10.1177/019262339902700107. Toxicol Pathol. 1999. PMID: 10367670 Review.

3

An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.

Poulet FM, Wolf JJ, Herzyk DJ, DeGeorge JJ. Poulet FM, et al. Among authors: herzyk dj. Birth Defects Res B Dev Reprod Toxicol. 2016 Apr;107(2):108-19. doi: 10.1002/bdrb.21176. Epub 2016 Apr 7. Birth Defects Res B Dev Reprod Toxicol. 2016. PMID: 27062127 Review.

4

A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.

Plitnick LM, Hutchins B, Dubey S, Li N, Amin RP, Born S, Mangadu R, Phillips JH, Sriram V, Herzyk DJ. Plitnick LM, et al. Among authors: herzyk dj. J Immunotoxicol. 2020 Dec;17(1):175-185. doi: 10.1080/1547691X.2020.1826020. J Immunotoxicol. 2020. PMID: 33078980

5

Adequate immunotoxicity testing in drug development.

Herzyk DJ, Gore ER. Herzyk DJ, et al. Toxicol Lett. 2004 Apr 1;149(1-3):115-22. doi: 10.1016/j.toxlet.2003.12.026. Toxicol Lett. 2004. PMID: 15093256

6

Preclinical safety of recombinant human interleukin-18.

Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ. Herzyk DJ, et al. Toxicol Pathol. 2003 Sep-Oct;31(5):554-61. doi: 10.1080/01926230390226681. Toxicol Pathol. 2003. PMID: 14692624

7

The T-dependent antibody response to keyhole limpet hemocyanin in rodents.

Plitnick LM, Herzyk DJ. Plitnick LM, et al. Among authors: herzyk dj. Methods Mol Biol. 2010;598:159-71. doi: 10.1007/978-1-60761-401-2_11. Methods Mol Biol. 2010. PMID: 19967512

8

Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.

Piccotti JR, Lebrec HN, Evans E, Herzyk DJ, Hastings KL, Burns-Naas LA, Gourley IS, Wierda D, Kawabata TT. Piccotti JR, et al. Among authors: herzyk dj. J Immunotoxicol. 2009 Mar;6(1):1-10. doi: 10.1080/15476910802656440. J Immunotoxicol. 2009. PMID: 19519157

9

Immunopharmacology of recombinant human interleukin-18 in non-human primates.

Herzyk DJ, Soos JM, Maier CC, Gore ER, Narayanan PK, Nadwodny KL, Liu S, Jonak ZL, Bugelski PJ. Herzyk DJ, et al. Cytokine. 2002 Oct 7;20(1):38-48. doi: 10.1006/cyto.2002.1978. Cytokine. 2002. PMID: 12441145

10

Tumor necrosis factor primes neutrophils for hypochlorous acid production.

She ZW, Wewers MD, Herzyk DJ, Sagone AL, Davis WB. She ZW, et al. Among authors: herzyk dj. Am J Physiol. 1989 Dec;257(6 Pt 1):L338-45. doi: 10.1152/ajplung.1989.257.6.L338. Am J Physiol. 1989. PMID: 2558582

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results